Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016
Dateline City:
KENILWORTH, N.J.
Presentations Include Results from Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the planned presentations of data from the company’s
broad chronic hepatitis C virus (HCV) clinical development programs at
the upcoming International
Liver Congress™ 2016.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Merck MRK NYSE:MRK ZEPATIER Source Type: news
More News: Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Politics | Study | Urology & Nephrology